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IRE1α and iGf signaling predict 
resistance to an endoplasmic 
reticulum stress-inducing drug in 
glioblastoma cells
Jeffrey J. Rodvold1, Su Xian  2, Julia nussbacher3, Brian tsui  2,  
T. cameron Waller  2, Stephen C. Searles1, Alyssa Lew1, pengfei Jiang4, ivan Babic4, 
natsuko nomura4, Jonathan H. Lin  5, Santosh Kesari  4 ✉, Hannah carter  2 ✉ & 
Maurizio Zanetti1 ✉
To date current therapies of glioblastoma multiforme (GBM) are largely ineffective. The induction of 
apoptosis by an unresolvable unfolded protein response (UPR) represents a potential new therapeutic 
strategy. Here we tested 12ADT, a sarcoendoplasmic reticulum Ca2+ Atpase (SeRcA) inhibitor, on 
a panel of unselected patient-derived neurosphere-forming cells and found that GBM cells can be 
distinguished into “responder” and “non-responder”. By RNASeq analysis we found that the non-
responder phenotype is significantly linked with the expression of UPR genes, and in particular ERN1 
(IRE1) and ATF4. We also identified two additional genes selectively overexpressed among non-
responders, IGFBP3 and IGFBP5. CRISPR-mediated deletion of the ERN1, IGFBP3, IGFBP5 signature 
genes in the U251 human GBM cell line increased responsiveness to 12ADT. Remarkably, >65% of GBM 
cases in The Cancer Genome Atlas express the non-responder (ERN1, IGFBP3, IGFBP5) gene signature. 
Thus, elevated levels of IRE1α and IGFBPs predict a poor response to drugs inducing unresolvable UPR 
and possibly other forms of chemotherapy helping in a better stratification GBM patients.
Glioblastoma (GBM) is a devastating, rapidly fatal disease whose survival rate has not improved much in recent 
years relative to other tissues. With the current standard of care for newly diagnosed GBM of surgical resection 
followed by temozolomide and radiotherapy, the expected median survival remains under two years1. This inade-
quacy leaves open the necessity for novel therapeutic approaches targeting the signaling programs GBM cells rely 
on to acquire chemoresistance and survive in the face of various challenges in the tumor microenvironment, e.g., 
hypoxia, radiation therapy, and chemotherapy (temozolomide).
In mammalian cells the unfolded protein response (UPR) represents a powerful homeostatic signaling mech-
anism and an adaptive cellular response to the accumulation of mis- or unfolded protein within the endoplasmic 
reticulum (ER)2. This homeostatic mechanism regulates the balance between cell survival and apoptosis such that 
if adaptation/restoration to proteostasis fails, the apoptotic program is activated2. This evolutionarily conserved 
signaling complex is mediated by three initiator/sensor ER transmembrane molecules: inositol-requiring enzyme 
1 (IRE1α), PKR-like ER kinase (PERK), and activating transcription factor 6 (ATF6), which, in the unstressed 
state, are maintained in an inactive state through association with 78 kDa glucose-regulated protein (GRP78)3. 
Upon activation of the UPR, PERK phosphorylates eIF2α, resulting in the selective inhibition of translation. 
Contextually, IRE1α autophosphorylates to activate its endonuclease domain, resulting in the cleavage of Xbp-1 
to generate a spliced Xbp-1 isoform (Xbp-1s), which drives the production of various ER chaperones to restore 
ER homeostasis. IRE1α‘s RNase domain can also cause endonucleolytic decay of many ER-localized mRNAs 
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through a phenomenon termed regulated IRE1-dependent decay (RIDD)4. ATF6 translocates to the Golgi where 
it is cleaved into its functional form, and activates transcriptionally XBP1 to restore ER homeostasis5. In solid 
tumors the UPR develops in response to special local environmental conditions such as nutrient deprivation, 
hypoxia, oxidative stress, but also viral infection (e.g., HBV, HCV, and HPV) or genomic abnormalities such as 
aneuploidy6.
Unlike untransformed somatic cells, tumor cells are already programmed for self-renewal and resist-
ance to DNA damage through the activation of telomerase7,8. Consequently, using cell-autonomous or 
cell-nonautonomous mechanisms, tumor cells leverage the UPR to further adapt to unfavorable microenviron-
mental conditions and develop resistance to therapy9–11. GBM tumor aggressiveness and chemoresistance corre-
lates with elevated levels of GRP7812 or IRE1α13,14, but not PERK. Furthermore, XBP1 splicing or RIDD activation 
have been found to correlate with different GBM phenotypes and tumor growth characteristics, suggesting that 
single UPR elements are points of vulnerability that could be exploited therapeutically to cause cell death and 
tumor arrest15. However, since no FDA-approved drugs exist to inhibit a specific UPR pathway16, an attractive 
alternative therapeutic approach is to induce substantial ER stress to drive the UPR’s apoptotic, rather than adap-
tive, signaling17. This can be realized, for instance, through the inhibition of the sarcoendoplasmic reticulum 
calcium transport ATPase (SERCA), which ensues in an acute depletion of Ca++ in the ER and the induction of a 
supra-physiological UPR. The pro-drug G-202 can accomplish this by releasing the active component 12ADT, a 
thapsigargin analogue, upon activation18.
Based on this reasoning, we studied the responsiveness of patient-derived GBM neurospheres to 12ADT. 
Strikingly, we found unique transcriptional signatures distinguishing responder from non-responder phenotypes. 
We further investigated the genes contained within these signatures for their relative contribution to 12ADT 
mediated cytotoxicity. These results provide novel insights into the transcriptional networks of GBM cells in 
relation to their sensitivity to treatment, hence establishing new predictive criteria for the treatment of patients 
with GBM.
Results
GBM cells respond differentially to 12ADT.  A new and potentially effective approach to drive glioblas-
toma (GBM) cells to apoptosis is to induce an acute and unresolvable ER stress response. Mipsagargin (G-202) 
is a prodrug that is hydrolyzed by prostate specific membrane antigen (PSMA), which is highly expressed in the 
stroma of 75% of brain tumors19 relative to normal brain tissue. PSMA hydrolysis releases G-202’s active compo-
nent, 8-O-(12-aminododecanoyl)-8-0 debutanoylthapsigargin (12ADT), a synthetic analogue of thapsigargin, 
which through its inhibition of the sarcoendoplasmic reticulum Ca2+ ATPase (SERCA) is a canonical and potent 
inducer of ER stress20. A potent in situ dose of 12ADT generates unresolvable ER stress in tumor cells driving a 
pro-apoptotic UPR. Thus, 12ADT could serve as novel chemotherapeutic to drive apoptosis in GBM cells. To test 
this hypothesis, we treated eight unique patient-derived GBM neurosphere forming cell lines for 48 hours with 
low doses (0.5–1 µM) of 12ADT and probed survival through flow cytometric detection for incorporation of the 
cell death marker, 7-aminoactinomycin D (7AAD) (Fig. 1A).
We found a striking variation in sensitivity to 12ADT across the eight neurosphere lines, with three being 
very sensitive (GBM4, GBM8, BT70) and five being resistant (SK102, SK262, SK429, SK748, SK987). Hereunder, 
we refer to these two groups as responder (R) and non-responder (NR). To investigate these results further, we 
treated R and NR neurosphere lines with increasing concentrations of 12ADT over 72 hours and determined 
EC50 values based on the incorporation of Alamar Blue stain for cell viability (Fig. 1B). The use of thapsigargin 
instead of 12ADT produced comparable results, suggesting that the R and NR phenotypes are due to SERCA 
inhibition (Fig. 1C). Importantly, the prodrug itself (G-202) did not induce substantial cytotoxicity in a R neu-
rosphere line, likely due to their low PSMA expression (Supplementary Fig. 1). Also, we could not attribute the 
different response to 12ADT to mutations in the SERCA gene. We used a Genome Analysis Toolkit (GATK)21 
to call variants in RNASeq data and did not find biases in the SERCA gene except one mutation in SK429 cells, 
suggesting that the R and NR phenotypes are not function of variability in the SERCA gene. Annexin V staining 
in representative R and NR neurosphere lines confirmed that 12ADT induced apoptosis in a large proportion of 
R cells (Fig. 1D), consistent with the known mechanism of UPR mediated cell death2.
On the basis of the difference in 12ADT-induced cytotoxicity between R and NR neurosphere lines, we 
hypothesized the involvement of different UPR genes in these groups. We found no significant differential expres-
sion in the key UPR genes GRP78, CHOP, and spliced XBP-1 (XBP-1s) between R and NR neurosphere lines 
after a 48 hour treatment with 12ADT (Fig. 1E). Next, we interrogated the expression of several UPR proteins 
by Western blot. We began with the master regulator of the UPR, GRP78 (HSPA5), the expression of which 
correlates with poorer survival of GBM patients (Supplementary Fig. 2) and was previously reported to confer 
chemoresistance in glioma cells13. We also analyzed the PERK pathway due to its role in chemoresistance in 
prostate cancer cells11 and its central role in coordinating UPR-associated apoptosis. While expression of these 
targets increased upon 12ADT treatment, we again did not find an expression pattern distinguishing R and NR 
neurosphere lines (Fig. 1F). Collectively, these data suggest that the differential susceptibility to 12 ADT treatment 
could not be explained by the perturbation of the expression of a single UPR element alone.
Differential UPR signatures in responder and non-responder neurospheres.  The absence of clear 
differences in GRP78 and PERK-associated proteins in R versus NR neurosphere lines led us to consider a more 
complex expression signature distinguishes the R/NR phenotypes. To that end, we isolated total RNA from the 
eight GBM neurosphere lines grown under homeostatic cell culture conditions (i.e., without treatment) as well 
as healthy brain tissue to serve as a negative control and performed RNASeq analysis. First, we evaluated the 
transcriptional similarity across replicates. We found that normal healthy controls clustered separately from the 
neurosphere lines, and that R neurosphere lines clustered more tightly than NR neurosphere lines (Fig. 2A). In 
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a transcriptome-wide analysis, we also found distinct clusters by principal component analysis (Supplementary 
Fig. 3). We next interrogated the expression of 85 UPR-associated genes (Supplementary Table 1) across samples 
and found that an unbiased hierarchical clustering was able to distinguish R neurosphere lines unambiguously 
from NR (Fig. 2B). When we examined UPR activity at the global level on the basis of an aggregate z-score of 
all eighty-five genes in this pathway, we found that the cumulative expression of UPR genes was higher in NR 
compared to R neurospheres lines (p < 0.033; Fig. 2C). From this global analysis, we sought to identify indi-
vidual genes that were driving this observation. We found that NR neurosphere lines had a significantly higher 
expression in 19 UPR associated genes after multiple testing correction, including ATF4 (p < 0.04) and ERN1 
(p < 0.05) whereas nine other genes were overexpressed in R neurosphere lines relative to NR (Supplementary 
Table 1). Transcripts for genes in the ATF6 pathway, including ATF6 (p > 0.93) itself and its upstream activator 
Figure 1. Differential toxicity of 12ADT across neurosphere lines. (A) Flow cytometric determination of 
GBM neurosphere line survival as determined by 7AAD positivity after 48 hour treatment with specified 
concentration of 12ADT. *P ≤ 0.05, ***P ≤ 0.001, Student’s t test (paired two-tailed). These results are 
representative of two independent experiments. Distribution of EC50 values between Responder (R) and 
Nonresponder (NR) neurosphere lines treated with either (B) 12ADT or (C) thapsigargin (Tg) for 72 hours 
and processed for viability by Alamar Blue absorbance. (D) Annexin V apoptosis staining of representative 
responder (GBM4) and nonresponder (SK987) after 48 hour treatment of 12ADT at 1 μM. (E) RT-qPCR 
of UPR associated genes in GBM neurosphere lines with specified concentration of 12ADT after 48 hour 
treatment (n = 2). Gene expression was normalized to each line’s respective 0 µM condition to determine 
relative quantification (RQ). (F) Western blot analysis of GBM neurosphere cell lines treated (+) or untreated 
(−) with 12ADT at 0.5 μM after 48 hours. Each data point is a single experiment with three replicates, and is 
representative of two independent experiments.
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GRP78 (p > 0.33), showed no significant differences between R and NR neurosphere lines, suggesting that this 
pathway played no central role in 12ADT sensitivity. We also found no significant difference in XBP1 (p > 0.66) 
expression. We conclude that under homeostatic conditions, R and NR neurosphere lines possess unique genetic 
UPR signatures, and that the increased constitutive expression of two genes - ATF4 and ERN1- is associated with 
increased resistance to 12ADT cytotoxicity.
We were intrigued that both ERN1 (the gene coding for IRE1) and ATF4 were increased in the NR group over 
the R group. Recent reports have suggested that ERN1 drives a variety of tumorigenic characteristics such as 
adhesion/migration and inflammation and correlates with reduced survival in GBM patients15. Another report 
suggested a functional link between expression of ATF4 and ERN1 activity22. Therefore, we posited that inhibiting 
the IRE1 pathway would increase sensitivity to 12ADT in NR neurosphere lines. To test this hypothesis, we evalu-
ated the relative roles of IRE1α and PERK pathways in the sensitivity of neurosphere lines to 12ADT using phar-
macological inhibition with 4μ8C and GSK2656157. 4μ8C19 is an IRE1α RNAse inhibitor, and GSK265615720 
inhibits PERK autophosphorylation and consequently attenuates the expression of the downstream genes ATF4 
Figure 2. Differential expression of UPR genes predicts 12ADT sensitivity. (A) Whole transcriptome-based 
unsupervised clustering of neurosphere lines and normal control samples. Normal and responder samples form 
distinct clusters, while nonresponder neurosphere lines cluster more weakly, suggesting more inter-sample 
transcriptional heterogeneity. (B) A heatmap displaying sample clustering based on the z-scored expression 
of 85 UPR genes. Unsupervised hierarchical clustering based on UPR gene expression grouped samples 
according to status with a single outlier among nonresponder neurosphere lines (SK987). (C) Comparison of 
aggregated z-scored UPR gene expression shows that the UPR is overall elevated in nonresponder neurosphere 
lines relative to responder lines. Normalized cell survival of (D) responder or (E) nonresponder neurosphere 
lines treated with 12ADT (0.5 μM) in the absence or presence of IRE1α inhibition (4μ8C) or PERK inhibition 
(GSK2656157). Survival determined by flow cytometry for 7AAD negativity and normalized by percent live 
(7AAD−) population of unstimulated, inhibited condition (n = 2 per group). *P ≤ 0.05, **P ≤ 0.01, Student’s t 
test (paired two-tailed). Data representative of three independent experiments.
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and CHOP. We treated the R and NR neurosphere lines with each inhibitor in the absence or presence of 12ADT 
for 48 hours and measured cell viability by flow cytometry. GSK2656157 treatment protected R neurosphere lines 
from 12ADT-mediated cell death, perhaps owing to the established role of the PERK pathway in mediating ER 
induced apoptosis (Fig. 2D). On the other hand, we found that treatment with 4μ8C alone reduced the viability 
of all three R neurosphere lines and increased their sensitivity to 12ADT (Fig. 2D). Surprisingly, 4μ8C alone or 
in combination with 12ADT at moderate concentrations (0.5 μM) did not affect 12ADT sensitivity in NR neuro-
sphere lines (Fig. 2E). Together, these results imply that IRE1α RNase activity promotes resistance to 12ADT in 
R, but not NR neurosphere lines.
A link between the UPR and insulin growth factor (IGF-1) signaling.  Because neither inhibition of 
the IRE1α or PERK pathways accounted for a differential sensitivity in NR neurosphere lines, we looked beyond 
UPR associated genes and performed a weighted gene correlation network analysis (WGCNA) to identify puta-
tive gene signaling networks and assess their roles in 12ADT responsiveness23. This WGCNA analysis detected 
modules of co-expressed genes and assigned an eigengene score for each module to represent its gene expres-
sion profile23. We then assigned Pearson correlation coefficients for each module’s eigengene expression across 
the experimental groups, including R and NR GBM neurosphere lines and healthy brain tissue (Fig. 3A). This 
analysis identified two modules, MEBlue and MEBrown, which showed the strongest opposing correlation coef-
ficients for R versus NR status. These modules comprised genes associated with epithelial cell motility (MEBlue) 
(Fig. 3B) and protein metabolic processes (MEBrown), respectively (Supplementary Fig. 4). Further investigation 
of the most differentially correlated genes within these modules identified cyclin dependent kinase inhibitor 2 A 
(CDKN2A) along with two genes in the insulin growth factor 1 (IGF-1) signaling pathway, IGF binding protein 
3 (IGFBP3) and IGF binding protein 5 (IGFBP5) (Fig. 3C). CDKN2A (p < 1e-10) was expressed at much higher 
levels in R relative to NR neurosphere lines (Fig. 3C, Supplementary Fig. 5). However, since this gene is com-
monly deleted in GBM24, we chose to pursue targets that would be more translationally relevant, since CDKN2A 
is likely undruggable. Specifically, IGFBP3 (p < 0.05) and IGFBP5 (p < 0.001) showed increased expression in NR 
compared to R neurosphere lines (Fig. 3C). Therefore, we hypothesized that IGF-1-mediated signaling may be 
involved in resistance to 12ADT. To that end, we treated R and NR neurosphere lines with 12ADT in the absence 
or presence of the IGF-1 receptor (IGF-1R) inhibitor NVP-AEW54125 for forty-eight hours and determined cell 
viability. While NVP-AEW541 was relatively well tolerated in both R (Fig. 3D) and NR (Fig. 3E) groups, its addi-
tion enhanced 12ADT-mediated cytotoxicity both in R and NR neurosphere lines.
Although the exact relationship between IGF-1R and the UPR is not well established, GRP78 was recently 
identified as a downstream target of IGF-1R signaling26, suggesting that GRP78 could mediate anti-apoptotic and 
growth promoting effects. To test this possibility, we performed surface staining for IGF-1R (CD221) on R and 
NR neurosphere lines but found no clear pattern distinguishing the two groups (Fig. 3F), suggesting that surface 
expression of IGF-1R does not contribute to differential responsiveness to 12ADT during IGF-1R inhibition. To 
determine if bioavailability of IGF-1 affects 12ADT resistance, we treated R neurosphere lines with 12ADT in 
medium supplemented with increasing concentrations (25, 50, 100 ng/ml) of IGF-1. The addition of IGF-1 to R 
neurosphere lines increased resistance to 12ADT but only moderately (Fig. 3G).
cRiSpR validates the role of ERN1 and IGFBP3/5 in the NR phenotype.  Collectively, the RNA-Seq 
expression and pharmacological inhibition studies suggested that IRE1α and IGF-1 signaling contributed to 
12ADT sensitivity. To further validate the contribution of these pathways to 12ADT-mediated cytotoxicity, we 
designed CRISPR guides against three target genes (ERN1, IGFBP3, IGFBP5) and transfected them separately 
into U251 glioblastoma cells. The change from patient derived neurosphere lines to immortalized human glio-
blastoma U251 line became necessary due to very poor transfection efficiency of the neurosphere lines. We con-
firmed gene knockout using Western blotting (Fig. 4A) and PCR on genomic DNA (Fig. 4B). The deletion of 
each of these genes augmented 12ADT cytotoxicity relative to the parental line across increasing concentra-
tions of 12ADT, with the strongest effect observed in the IGFBP5 knockout (Fig. 4C). To further substantiate 
these observations and also identify any cross-functionality among ERN1, IGFBP3, IGFBP5, we treated U251 
CRISPR-deleted clones with 12ADT in the absence (Fig. 4D) or presence of 4μ8C (Fig. 4E) or NVP-AEW541 
(Fig. 4F). Whereas 4μ8C treatment slightly increased the 12ADT EC50 in ERN1−/− clone (1.6-fold), it slightly 
decreased the EC50 in the parental U251 line (1.4-fold) and in both IGFBP clones (1.6-fold for IGFBP3−/−, 
and 1.9-fold for IGFBP5−/−). This is perhaps due to the effect of 4µ8c on other target mRNAs. Strikingly, the 
inhibition of IGF-1R with NVP-AEW541 dramatically enhanced 12ADT cytotoxicity for each knockout cell 
line (56-fold for parental, 224-fold for ERN1−/−, 1101-fold for IGFBP3−/−, and 997-fold for IGFBP5−/−). 
These observations demonstrate how important these two new pathways are in the response of GBM cells to 
UPR-inducing stressors.
Estimating the generalizability of 12ADT response.  Collectively, our results predict that GBM 
patients with lower ERN1, IGFBP3, and IGFBP5 expression would respond more favorably to a UPR-based treat-
ment such as G-202/12ADT. To determine what fraction of GBM patients exhibit such a gene expression profile, 
we probed one hundred and forty-three GBM samples within The Cancer Genome Atlas (TCGA). We trained a 
simple support vector machine (SVM) classifier on z-scored expression levels of ERN1, IGFBP3, and IGFBP5 in R 
and NR neurosphere lines, treating replicates as independent samples. Given the small sample size (n = 16) avail-
able for training, the resulting classifier may provide a somewhat biased estimate on potential response. Using 
a cross validation approach where both replicates of each sample were withheld from the training, the classifier 
was able to classify responder status correctly in the remaining fourteen out of sixteen samples. We then applied 
this SVM classifier to GBM samples from TCGA (n = 143) (Fig. 4G). Our classifier suggested that 34% (n = 49) 
of GBM tumors could potentially be sensitive to UPR-based therapies, whereas the remaining 66% would require 
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additional interventions targeting IGF-1 signaling or IRE1α signaling. Finally, we performed survival analysis 
using the progression free survival (PFS) data for GBM 94 samples from TCGA. Since lower expression was asso-
ciated with response to treatment, we speculated that lower expression of these genes in general could indicate 
less aggressive disease. Of the three genes, the IGFBP3 low group had a significantly better survival status than the 
IGFBP3 high group (p = 0.03; one-tailed long-rank test; Supplementary Fig. 6A). Differences in progression free 
survival of the other two genes did not reach significance (Supplementary Fig. 6B).
Figure 3. IGF signaling contributes to 12ADT toxicity. (A) Heatmap displaying Pearson correlation coefficients 
between eigengene profiles and sample traits for modules detected by WGCNA. Samples were divided into 
2 groups according to responder or control status before evaluating correlation. MEBlue and MEBrown 
modules display the strongest opposing correlation between responder and nonresponder neurosphere lines. 
(B) Heatmap of gene expression across samples for genes belonging to the MEBlue module shows differential 
expression of genes relative to response. (C) Comparison of expression levels between responder and 
nonresponder neurosphere lines of selected genes that show strong differential expression in MEBlue (IGFBP3, 
IGFBP5) and MEBrown (CDKN2A). (D) Normalized cell survival of three responder (GBM4, GBM8, BT70) 
and (E) three nonresponder neurosphere (SK102, SK262, SK748) lines treated with 12ADT (0.5 μM) in the 
absence or presence of IGF-1R inhibition (NVP-AEW541). Survival determined by flow cytometry for 7AAD 
negativity and normalized by percent live (7AAD−) population of unstimulated, inhibited condition (n = 2 per 
group) and are representative of three independent experiments. *P ≤ 0.05, **P ≤ 0.01, Student’s t test (paired 
two-tailed) (F) Detection of surface expression of CD221 (IGF-1R) in GBM neurosphere lines as determined by 
flow cytometry. (G) Normalized cell survival of responder cell neurosphere lines treated with 12ADT (0.5 μM), 
supplemented with increasing concentrations of IGF1, after 48 hour treatment. Survival determined by flow 
cytometry for 7AAD negativity and normalized by percent live (7AAD−) population of unstimulated condition 
where no IGF-1 supplementation occurred (n = 2 per group).
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Discussion
Glioblastoma is one of the most aggressive solid malignancies whose survival rate has not improved much in 
recent years relative to other malignancies. Beside conventional approaches (surgery, radiation, and temozolo-
mide), recent intervention attempts have leveraged immunotherapy. In this context, personalized neoantigen 
vaccination has met with immunological but not clinical responses27,28 and immune checkpoint inhibition29 
is most applicable to patients with mismatch repair (MMR) deficiencies, which are present in a very low per-
centage of GBM patients30. Immunotherapy also faces additional hurdles such as local immune suppression by 
macrophage-like cells31 and immune evasion due to PD-L1-expressing exosomes released by GBM cells32. Thus, 
alternative approaches are needed.
A new conceptual therapeutic approach in GBM is the induction of apoptosis by exacerbation of the UPR’s 
apoptotic signaling through the creation of massive, unresolvable ER stress. Although 12ADT is not likely to 
cross the blood brain barrier, the prodrug Mipsagargin (G-202), which targets the tumor vasculature is in clinical 
trial (NCT01056029)33. Using an unselected panel of patient-derived GBM neurosphere lines, we found that 
susceptibility to apoptosis by a SERCA inhibitor analogue of thapsigargin clearly distinguishes two populations 
Figure 4. Loss of ERN1, IGFBP3, IGFBP5 sensitize cells to 12ADT toxicity. (A) Western blot detection of IRE1 
in U251 parental and CRISPR deleted ERN1, IGFBP3, IGFBP5. (B) PCR detection of IGFBP3 and IGFBP5 
of U251 parental and CRISPR deleted ERN1, IGFBP3, IGFBP5. (C) Percent survival of U251 parental (WT) 
or CRISPR U251 cells during increasing concentrations of 12ADT after 48 hours. Survival determined by 
flow cytometry for 7AAD negativity (n = 2 per group) and are representative of at least three independent 
experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 Student’s t test (paired two-tailed). (D–F) Normalized percent 
survival and corresponding EC50 values of U251 parental or CRISPR cell lines titration of 12ADT after 48 hours 
in absence (D) or presence of IRE1α inhibition (E) or IGF-1R inhibition (F) (n = 3 per condition). Percent 
survival determined by Alamar Blue absorbance values (n = 3) normalized at 12ADT 0.00001 μM absorbance 
value for each line. (G) Predicted 12ADT response status for 143 GBM samples in the TCGA GBM dataset.
8Scientific RepoRtS |         (2020) 10:8348  | https://doi.org/10.1038/s41598-020-65320-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
of responder (R) and non-responder (NR) conditions, which were also distinguished in the same manner by 
temozolomide treatment (Supplementary Fig. 7). Characteristic of the NR phenotype was a significantly higher 
expression of 19 UPR genes including ERN1 and ATF4 compared to the R phenotype. The tumor promoting role 
of ERN1 is consistent with previous reports that IRE1α activity correlates in a cause-effect relationship with GBM 
aggressiveness14,15,34. Thus, heightened levels of IRE1α, a pro-survival factor35, causes resistance to UPR-induced 
apoptosis in GBM neurosphere lines.
Remarkably, transcriptional profiling and network analysis of R vs. NR neurosphere lines identified additional 
differentially-expressed gene networks. Within these, two genes, IGFBP3 and IGFBP5, belonging to the IGF-1 sig-
naling pathway, have been previously implicated in tumorigenesis36,37 including GBM38. IGFBPs can drive tumor-
igenesis by increasing IGF-dependent signaling that in turn increases cancer cell proliferation and survival39. Of 
interest, Ecuadorian people with the Laron syndrome, a rare form of short stature with a mutation in the growth 
hormone (GH) receptor and extremely low IGF-1 serum levels have very low susceptibility to cancer40, stressing 
a central role for the IGF-IGFBP axis in fueling cell proliferation and opposing apoptosis in cancer cells. Of note 
also is the fact that IGF-1 signaling positively regulates the expression of GRP7826, consistent with the fact that 
HSPA5 (GRP78) expression in TCGA correlates with poorer survival of GBM patients (Supplementary Fig. 2). 
In addition, IGF-1 could potentiate replicative activity of GBM cells by stimulating telomerase41. Since TERT 
promoter mutations occur in 80% of GBM42, causing per se an increase in TERT transcription, the present data 
suggest that a constitutively high IGF-1 signaling could contribute to high telomerase activity in GBM cells.
We found that NR neurosphere lines had very low expression levels of CDKN2A compared to R neuros-
phere lines, implying a direct correlation between CDKN2A status and responder potential. However, separate 
inhibition of either IRE1α or IGF-1 signaling increased sensitivity to 12ADT, suggesting an unanticipated inter-
dependence between the IRE1α pathway and the IGF-1 axis. Therefore, a homozygous deletion of CDKN2A in 
chromosome band 9p2, which is present in ~58% of GBM cases24, should have little role in attempts to convert a 
NR phenotype to a R phenotype.
In conclusion, the analysis of patient-derived GBM neurosphere lines enabled us to accurately profile 
responder vs. non-responder phenotypes. We found that sensitivity to a UPR inducing prodrug may be hin-
dered not only by constitutively-high levels of activation of the UPR but also by a heightened expression of genes 
encoding proteins central to IGF-1 signaling. Remarkably, the NR signature was validated in TCGA and found to 
account for>65% of GBM cases. Therefore, new UPR-based therapies need to take into consideration the role of 
elevated IRE1α and IGFBPs making it urgent to develop strategies to disable them, thereby decreasing resistance 
and increasing sensitivity to UPR therapies. It may be important to verify if the NR signature identified herein can 
also be used to predict other forms of treatment.
Materials and Methods
GBM tissue acquisition, processing, and culture of GSCs.  We have previously published on the ori-
gin and methods to generate the neurosphere lines used in this paper44. Briefly, GBM (grade IV glioma) tumor 
samples were obtained from adult human (>21 years) surgical patients without the exclusion of either sex or any 
ethnic/racial groups, under an approved UC San Diego Moores Cancer Center IRB (#IRB # 100936) protocol, 
with written, informed patient consent. These patient derived cell lines were made in Dr. Santosh Kesari labora-
tory under the protocol # identified herein. IRB ethical guidelines were strictly followed, and patient samples were 
de-identified. Tumor samples were immediately washed 2–3 times with 5–10 ml of PBS/NSC basal medium to 
remove blood and debris, and the tissue was minced for 1–3 minutes with a No. 10 scalpel blade. The minced tis-
sue was enzymatically dissociated by using 3–5 ml of pre-warmed Accutase® (Life Technologies) for 10–15 min-
utes in a 37 °C water bath. The solution was subsequently centrifuged, and 10–15 ml of basal medium was added 
to the tube and filtered through a 40 micron cell strainer to remove clumps and debris. After further washing cells 
were plated in NSC medium supplemented with 20 ng/ml EGF, 10 ng/ml bFGF and heparin (2 ng/ml), antibiotics 
added, and the cultures incubated at 37 °C in 5% CO2.
Passaging and expansion of patient GBM derived neurospheres.  The Methods used culture these 
neurosphere cell lines were published previously43–46. We cultured patient-derived neurosphere cell lines GBM4, 
GBM8, SK1035, SK987, SK892, SK429 and SK262 as previously described43–46. When the neurospheres reached 
an average size of 150–200 μm in diameter, subculture was initiated. The content of each flask was removed and 
placed in an appropriately sized sterile tissue culture tube, and centrifuged at 190 g for 6 min at room temperature. 
The supernatant was removed and the pellet dissociated to create a single cell suspension. The cell suspension was 
centrifuged, the supernatant was aspirated, and the cells resuspended in 1 ml of NSC medium and incubated at 
37 °C in 5% CO2.
Cell culture.  Neurosphere lines were maintained on ultra-low attachment tissue culture plates (Corning) and 
grown in Neurocult Basal Medium (StemCell) supplemented with EGF (20 ng/mL), FGF (10 ng/mL), 0.002% 
Heparin, and 1% Pencillin/Streptomycin. Neurosphere lines were dissociated using Accutase digestion. 293 T and 
U251 cell lines were maintained in DMEM supplemented in 10% FBS, 1% Pencillin/Streptomycin. All cultures 
were confirmed to be mycoplasma free by PCR detection (Southern Biotech).
Establishment of EC50 values.  EC50 values were calculated according to procedures published previ-
ously43–46. GBM neurosphere cells were dissociated to single cell suspension and plated on ultra low-adherence 96 
well plates at 2000 cells per well for drug testing. 12ADT and thapsigargin (Tg) drugs were serially diluted in log 
scale and added to 96 well plates to final concentration at 10, 1, 0.1, 0.01, 0.001, 0.0001, 0.00001 μM. After 72 hours 
of incubation with drug, the inhibition of cell growth was quantified by the Alamar Blue viability assay. Briefly, 
after incubation, Alamar Blue (#BUF012B, AbD Serotec) was added directly to the culture medium according 
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to manufacturer specifications, and the fluorescence measured at 560/590 nm to determine the number of via-
ble cells using TECAN (Infinite M200, Tecan Group Ltd.). Values were normalized to 0.00001 uM reading and 
EC50 values were determined by performing nonlinear regression analysis using commercially available software 
(Prism®, Graphpad Software, La Jolla, CA).
CRISPR design.  CRISPR plasmid design, generation, and validation were performed according to Methods 
and procedures published previously11. Briefly, for each gene of interest, two pairs of Cas9 guides were designed 
using the CHOPCHOP (Montague, TG Nucleic Acids Res 2014) software (available at http://chopchop.cbu.uib.
no/) CRISPR guide sequences and primers against target region are detailed in Supplementary Table 2. Guides 
were cloned into the SpCas9–2A-GFP (px458) backbone modified to contain an EIF1α promoter (px458-ef1α)47. 
Briefly, Cas9 guides were purchased as oligonucleotides from IDT. These oligonucleotide guide pairs (with over-
hangs 5’CACCG on the forward strand and 5’AAAC, 3’C on the reverse strand) were phosphorylated, annealed 
and ligated into BbsI-digested px458 backbone. The ligated plasmid was then transformed into DH5α bacteria 
and grown on Carbenecillin plates overnight at 37 C. Single colonies were picked and cultured overnight and the 
plasmids isolated by mini or midi-prep (Invitrogen), and sequence validated. Transfection of CRISPR plasmids: 
293XT and U251 cells were grown in DMEM with 10% FBS. 24 h prior to transfection, 8×10^4 cells/cm2 were 
seeded onto 6-well plates. The following day, the cells were transfected with the guide-containing px458-ef1a 
plasmids using Lipofectamine 3000 (ThermoFisher) according to manufacturer protocol. 72 h post-transfection, 
cells were FACS sorted for GFP + expression. Cells were then cultured in DMEM with 10% FBS with Pen/Strep 
for at least 1 week prior to validation and use in downstream analysis. To demonstrate Cas9 efficiency genomic 
DNA (gDNA) was isolated and PCR amplified using GoTaq (Promega) according to manufacturer instructions. 
To validate knockout of ERN1, western blot analysis was performed. Briefly, lysates of each cell line were prepared, 
separated by PAGE, transferred to a PVDF membrane, probed with monoclonal antibodies specific for IRE1α 
(Cell Signaling) or ACTB (Sigma), and imaged using HRP-conjugated secondary antibodies paired with Clarity 
Western ECL Substrate (BioRad). Since high quality monoclonal antibodies are not readily available for IGFBP3 
or IGFBP5, we were unable to confirm knockout of these genes at the protein level. Instead, genomic DNA was 
isolated and PCR amplified with GoTaq (Promega) according to manufacturer instructions, using primers 
designed to flank the deleted region of each gene (Supplementary Table 2). PCR product was then resolved on a 
2% agarose gel and imaged under UV.
Flow cytometry.  To determine cell viability, neurosphere cell lines or adherent cells lines were enzymatically 
dissociated through Accutase solution (Sigma) or TrypLE solution (Gibco), respectively. Cells were then washed 
in dPBS containing 1% BSA and 0.01% sodium azide and resuspended in wash buffer containing 7AAD at 20 ug/
ml. Apoptosis assays were performed on single-cell suspensions, stained with fluorescein isothiocyanate (FITC) 
- conjugated Annexin V and propidium iodide (PI), following the FITC Annexin V Apoptosis Detection Kit (BD 
Biosciences). Surface staining for IGF1-R was performed using the commercially available conjugated antibody 
for CD221 (eBioscience). PSMA status was determined using a commercially available PE-conjugated antibody 
(BioLegend). All flow data were acquired on a FACSCalibur flow cytometer (BD Biosciences) and analyzed using 
CellQuest Pro (BD Biosciences) and FlowJo software (Tree Star). Procedures used follow procedures published 
previously11.
Molecular biology.  Cells were harvested, dissociated, and resuspended in dPBS. For RNA-seq preparation, 
total RNA was extracted using RNeasy Mini isolation kit (Qiagen). For RT-qPCR analysis, RNA was harvested 
using Nucleospin RNA (Macherey-Nagel). RNA quality and purity were determined using Nanodrop and nor-
malized to equal concentrations to generated cDNA using High-Cap cDNA (Applied Biosystems). Endogenous 
controls of β-actin or the ribosomal subunit 18 s were used and relative quantification (RQ) expression was deter-
mined using the –ΔΔCT method. Methods are according to previously published protocols11.
RNA-seq analysis.  RNA was extracted from responder and non-responder cells using the Nucelospin RNA 
kit (Macherey Nagel). RNA sample purity was ascertained by the Nanodrop quantification method. Single end 
stranded RNA libraries were sequenced on an Illumina HiSeq. 4000. All samples and replicates were sequenced 
together on the same run. RNA-seq transcript quantification was performed with Sailfish version 0.9.1 using 
human reference transcriptome GRCh38 from Ensembl (URL: http://ftp.ensembl.org/pub/current_fasta/homo_
sapiens/cdna/Homo_sapiens.GRCh38.cdna.all.fa.gz) and default parameters. We performed principal compo-
nent analysis across all genes in SciKit-Learn version 0.19.1. Differential gene expression for 85 UPR genes from 
three Reactome pathways (R-HSA-381042.1, R-HSA-381038.2, R-HSA-381183.2) was determined using T-tests, 
implemented with Python package Scipy version 0.19.1 and p-values were adjusted for multiple testing using the 
Benjamini-Hochberg method. To obtain aggregate UPR expression values, unsigned z-scored expression values 
were summed across UPR genes in each replicate. WGCNA analysis was performed on whole transcriptome 
profiles with default parameters using the WGCNA R package version 1.61. Correlation of WGCNA modules 
with trait (Fig. 3A) was assessed based on the average Pearson correlation of module member gene expression 
level with sample classification using a 1 versus rest strategy such that correlation was first assessed for responders 
versus both non-responders and controls, then for non-responders versus both responders and controls and so 
on. To generate clustered heatmaps, expression values were clustered using agglomerative hierarchical clustering 
(Wards method) as implemented in the Seaborn clustermap function. All the Python analysis was done using 
Python version 2.6.
Western blotting.  Methods used were consistent with previously published protocols11. Briefly, cell lysates 
were harvested at specified time point and washed with ice-cold dPBS and suspended in RIPA lysis (Santa Cruz 
Biotechnology), supplemented with Halt Protease Inhibitor (Thermo). Cell lysates were lysed for 15 minutes on 
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ice and centrifuged at 14,000 g for 15 min, and the supernatants were collected. Lysate protein concentration 
was determined using the Pierce BCA Protein Assay Kit (Thermo Scientific). Samples were heat-denatured, and 
equal concentrations of protein were loaded onto a 4 to 20% Mini-PROTEAN TGX Precast Gels (Bio-Rad), 
electrophoresed, and transferred PVDF membranes in tris-glycine transfer buffer containing 20% methanol. 
Transfer membranes were blocked with 5% nonfat milk in tris-buffered saline (TBS) containing 0.1% Tween 20 
(TBS-T) for 1 hour at room temperature. The membranes were then incubated with the specified primary anti-
bodies overnight at 4 °C. Membranes were subsequently washed three times for 5 min at room temperature with 
TBS-T and incubated with a HRP–labeled secondary antibody in 5% nonfat milk for 1 hour at room temperature. 
Membranes were then three times washed with TBS-T in five minute intervals. Bound antibodies were detected 
by chemilluminescence reaction using Pierce ECL Blotting Substrate (Thermo). The following primary antibod-
ies were used: mouse monoclonal antibody to human GRP78 (BD Biosciences), rabbit monoclonal antibody to 
human PERK (Cell Signaling Technology), rabbit monoclonal antibody to phospho-eIF2α (Ser51) (Cell Signaling 
Technology), rabbit polyclonal antibodies to human ATF4 (CREB-2) (Santa Cruz Biotechnology), and HRP- 
conjugated goat antibodies to GAPDH (Santa Cruz Biotechnology). Secondary antibodies were HRP-conjugated 
anti-mouse IgG or anti-rabbit IgG (Santa Cruz Biotechnology).
Bioinformatic analyses.  (a) Projecting 12ADT response using TCGA GBM samples. In total six responder 
samples and 10 non-responder samples (treating replicates as independent samples) were used as a training set 
to fit a linear support vector machine classifier, using z-scored log2 TPM values for IGFBP3, IGFBP5 and ERN1 
as features. Due to the small sample size, to evaluate generalization error we applied a leave one sample out (both 
replicates) strategy to evaluate this simple model. This model was then applied to predict potential to respond to 
12ADT in 143 GBM samples in the TCGA. Prior to applying the model, GBM RNAseq data obtained from the 
Genomic Data Commons were processed to TPM using Sailfish version 0.9.1, log2 transformed and z-scored. The 
linear SVC model was implemented using the svm.LinearSVC module from the sklearn package version 0.19.1, 
python version 2.7.15. (b) Survival analysis. The following analysis was performed using. The regression analysis 
was performed using the survival package version 2.44–1.1 in R version 3.6.1. Progression-free survival (PFS) 
was calculated according to48. TCGA samples were divded into low, intermediate and high expression groups 
according to the 30th and 70th percentile of expression. Progression-free survival was then compared between the 
low and high expression groups using a one-tailed log-rank test, implemented using the logrank test function, 
specifying a one-tailed test using alternative = “less”, under the coin package, version 1.3–1.
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